greeksoup/ stocks
Stocks / United States / CVS / Q1 FY2025

CVS Health Corp. Q1 FY2025 results: revenue $94.6 billion, up 7.0% on the year

CVS Health Corp. (CVS) reported revenue of $94.6 billion for Q1 FY2025, the quarter ended 31 March 2025, up 7.0% on the same quarter a year earlier. Net income was $1.8 billion, up 59.8% on the year, and diluted earnings per share $1.41. The figures are the company's own, from the 10-Q it filed with the SEC on 1 May 2025.

Revenue$94.6 billionup 7.0%
Net income$1.8 billionup 59.8%
Diluted EPS$1.41
QuarterQ1 FY2025ended 31 March 2025

The quarter, against the one before and a year earlier

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Revenue94,58897,71088,437+7.0%
Cost of revenue51,05755,26848,073+6.2%
Gross profit43,53142,44240,364+7.8%
Gross margin46.0%43.4%45.6%
Operating income3,3742,3682,271+48.6%
Operating margin3.6%2.4%2.6%
Interest expense785758716+9.6%
Pre-tax income2,6172,1261,580+65.6%
Income tax835503456+83.1%
Effective tax rate31.9%23.7%28.9%
Net income1,7791,6441,113+59.8%
Net margin1.9%1.7%1.3%
Diluted EPS$1.41$1.30$0.88+60.2%

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Operating cash flow4,5561,8604,903-7.1%
Capital expenditure743768705+5.4%
Free cash flow3,8131,0924,198-9.2%
Free cash flow margin4.0%1.1%4.7%
Depreciation and amortisation1,1541,1471,138+1.4%
Share-based compensation126137137-8.0%
Buybacks0.00.03,027n/a
Dividends paid840838840+0.0%
Dividend per share$0.67$0.67$0.67+0.0%
Diluted shares, weighted1,264m1,262m1,267m-0.2%
Shares outstanding at period end1,262m1,260m1,252m+0.8%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Total assets255,585253,215249,743+2.3%
Cash and equivalents10,0768,5869,801+2.8%
Receivables39,62536,46932,217+23.0%
Inventory17,38518,10716,346+6.4%
Goodwill91,20391,27291,272-0.1%
Long-term debt including finance leases59,04060,52757,694+2.3%
Borrowings, as the company tags themn/a63,268n/an/a
Operating lease liabilities14,59414,89915,742-7.3%
Finance lease liabilitiesn/a1,295n/an/a
Shareholders' equity76,92975,56073,968+4.0%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue89,76493,81388,43791,23495,42897,71094,58898,915102,871105,693100,426106,096
Cost of revenue54,68857,41948,07349,99852,94855,26851,05754,00557,04559,06055,44458,862
Gross profit35,07636,39440,36441,23642,48042,44243,53144,91045,82646,63344,98247,234
Gross margin39%39%46%45%45%43%46%45%45%44%45%45%
Operating income3,6903,3732,2713,0458322,3683,3742,381-3,2072,1124,6804,703
Operating margin4%4%3%3%1%2%4%2%-3%2%5%4%
Interest expense693690716732752758785763784787774757
Pre-tax income3,0192,7051,5802,3371052,1262,6171,647-3,4821,3543,9383,977
Tax rate25%24%29%24%32%24%32%38%n/a-116%25%25%
Net income2,2612,0461,1131,77087.01,6441,7791,021-3,9752,9432,9432,979
Net margin3%2%1%2%0%2%2%1%-4%3%3%3%
Diluted EPS$1.75$1.59$0.88$1.41$0.07$1.30$1.41$0.80-$3.13$2.31$2.30$2.31
Operating cash flow2,716-2,6364,9033,089-7451,8604,5561,8977963,3904,2496,345
Capital expenditure545911705638670768743607698784849691
Free cash flow2,171-3,5474,1982,451-1,4151,0923,8131,29098.02,6063,4005,654
Buybacks-3.0-1.03,027-3.0-1.00.00.00.00.00.0n/an/a
Dividends paid779779840858837838840866846845847878
Shares outstanding1,287m1,288m1,252m1,256m1,258m1,260m1,262m1,267m1,270m1,271m1,273m1,278m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 31 March 2025, filed 1 May 2025, accession 0000064803-25-000013: the filing on EDGAR. All of CVS Health Corp.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install